Lifecore Biomedical
LFCR
103 hedge funds and large institutions have $226M invested in Lifecore Biomedical in 2025 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 26 reducing their positions, and 14 closing their positions.
284% more call options, than puts
Call options by funds: $879K | Put options by funds: $229K
31% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 26
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
13% more capital invested
Capital invested by funds: $199M → $226M (+$26.6M)
3% more funds holding
Funds holding: 100 → 103 (+3)
1.16% more ownership
Funds ownership: 65.01% → 66.17% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$862K |
| 2 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$679K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$612K |
| 4 |
BlackRock
New York
|
+$492K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$454K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$900K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$360K |
| 3 |
Squarepoint
New York
|
-$299K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$282K |
| 5 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$278K |
LFCR Hedge Fund Activity: Q4 2025 in Review
103 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q4 2025, worth a combined $226M — up 13% from $199M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new LFCR positions and 14 closed out — a net gain of 4 holders — while 34 added to existing stakes and 26 trimmed.
The largest buyer was Millennium Management, adding an estimated $862K. The largest seller was Royal Bank of Canada, cutting an estimated $900K.
- 103 institutional investors held Lifecore Biomedical (LFCR) as of Q4 2025, up from 100 in Q3 2025.
- Funds reported $226M of Lifecore Biomedical stock for Q4 2025, up 13% quarter-over-quarter.
- 18 funds opened new Lifecore Biomedical positions in Q4 2025 and 14 closed out, a net change of +4 holders.
- The largest Lifecore Biomedical buyer in Q4 2025 was Millennium Management, an estimated $862K added.
- The largest Lifecore Biomedical seller in Q4 2025 was Royal Bank of Canada, an estimated $900K sold.
Based on aggregated 13F filings for Q4 2025.